Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Express Scripts
Federal Trade Commission
Covington
Queensland Health
Chubb
Johnson and Johnson
Julphar
Teva
Moodys
US Department of Justice

Generated: August 18, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 201023

« Back to Dashboard
NDA 201023 describes JEVTANA KIT, which is a drug marketed by Sanofi Aventis Us and is included in one NDA. It is available from one supplier. There are three patents protecting this drug. Additional details are available on the JEVTANA KIT profile page.

The generic ingredient in JEVTANA KIT is cabazitaxel. There are thirteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the cabazitaxel profile page.

Summary for NDA: 201023

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:3
Formulation / Manufacturing:see details

Suppliers and Packaging for NDA: 201023

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
JEVTANA KIT
cabazitaxel
SOLUTION;IV (INFUSION) 201023 NDA Sanofi-Aventis U.S. LLC 0024-5824 0024-5824-11 1 KIT in 1 CARTON (0024-5824-11) * 5.7 mL in 1 VIAL, GLASS (0024-5823-15) * 5.7 mL in 1 VIAL, GLASS (0024-5822-01)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;IV (INFUSION)Strength60MG/1.5ML (40MG/ML)
Approval Date:Jun 17, 2010TE:RLD:Yes
Regulatory Exclusivity Expiration:May 17, 2020
Regulatory Exclusivity Use:
Patent:► SubscribePatent Expiration:Sep 26, 2021Product Flag?Substance Flag?Delist Request?Y
Patent:► SubscribePatent Expiration:Jun 10, 2026Product Flag?Substance Flag?Delist Request?Y

Expired Orange Book Patents for NDA: 201023

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sanofi Aventis Us
JEVTANA KIT
cabazitaxel
SOLUTION;IV (INFUSION)201023-001Jun 17, 2010► Subscribe► Subscribe
Sanofi Aventis Us
JEVTANA KIT
cabazitaxel
SOLUTION;IV (INFUSION)201023-001Jun 17, 2010► Subscribe► Subscribe
Sanofi Aventis Us
JEVTANA KIT
cabazitaxel
SOLUTION;IV (INFUSION)201023-001Jun 17, 2010► Subscribe► Subscribe
Sanofi Aventis Us
JEVTANA KIT
cabazitaxel
SOLUTION;IV (INFUSION)201023-001Jun 17, 2010► Subscribe► Subscribe
Sanofi Aventis Us
JEVTANA KIT
cabazitaxel
SOLUTION;IV (INFUSION)201023-001Jun 17, 2010► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.



Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Merck
Covington
Argus Health
McKesson
Federal Trade Commission
US Army
US Department of Justice
Harvard Business School
Mallinckrodt
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot